Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06800690 · ClinicalTrials.gov registry record

Impact of Menstrual Phase on Oral Glucose Sensitivity

A clinical trial, sponsored by Rutgers, The State University of New Jersey.

Completed
Registry status
22
Enrollment target

NCT06800690: Completed study, sponsored by Rutgers, The State University of New Jersey.

NCT06800690 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06800690 has completed, sponsored by Rutgers, The State University of New Jersey.

COMPLETED
Registry status
22 participants
Enrollment target

Study Summary

In this study we are determining whether the hormones associated with the phases of the menstrual cycle (menstruation \& ovulation) influence taste sensitivity to glucose. We hypothesized that women would be more sensitive to oral glucose as assessed by absolute detection threshold during ovulation than when assessed during menstruation. These phases of the cycle are associated with peak plasma estradiol levels and nadir estradiol levels. There is evidence that estrogen can increase the sensitivity of the metabolic signaling pathway of the pancreatic beta-islet cells to stimulate insulin release more readily when glucose is present by increasing sensitivity of the K-ATP channel to ATP. Since the same metabolic signaling pathway is reported to be present in taste tissue, we tested whether peak estrogen levels would enhance taste detection of glucose but not sweeteners that cannot generate ATP, such as sucralose or methyl-D-glucopyranoside (MDG).

Primary Outcome

Participants had an oral glucose detection threshold measured at menstruation (estrogen nadir) and peri-ovulation (estrogen peak). Men were tested twice two weeks apart over the same time frame as women.

Interventions

  • DIAGNOSTIC_TEST Urinary Estrogen Level

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-11-03
Est. Completion 2024-12-10

What the finished NCT06800690 record still lists

NCT06800690 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Urinary Estrogen Level is the first listed.

NCT06800690 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06800690 about?

NCT06800690 is a clinical study titled "Impact of Menstrual Phase on Oral Glucose Sensitivity". In this study we are determining whether the hormones associated with the phases of the menstrual cycle (menstruation \& ovulation) influence taste sensitivity to glucose. We hypothesized that women would be more sensitive to oral glucose as assessed by absolute detection threshold during ovulation ...

What is the current status of trial NCT06800690?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2021-11-03. Estimated completion is 2024-12-10.

What interventions are being tested in trial NCT06800690?

The interventions under investigation include: Urinary Estrogen Level (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06800690?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06800690, the US trial registry maintained by the National Library of Medicine. NCT06800690 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.